Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Health worker sorting prescriptions on shelves © Rumi Consultancy, World Bank

Similar stories

Ensitrelvir shows strong antiviral activity against COVID-19 in first head-to-head comparison with Paxlovid

The oral antiviral ensitrelvir is a highly effective treatment for COVID-19, showing potent in-vivo antiviral activity comparable to ritonavir-boosted nirmatrelvir (Paxlovid), say MORU, Mahidol and University of Oxford researchers in a major international study published in The Lancet Infectious Diseases.